培美曲塞联合洛铂或顺铂治疗晚期肺腺癌临床观察  

Clinical Observation on Pemetrexeddisodium Combined with Lobaplatin or Cisplatin in Treatment of Advanced Adenocarcinoma of Lung

作　　者：廖漓漓[1] 

机构地区：[1]桂林医学院附属医院,广西桂林541001

出　　处：《中医学报》2014年第B12期257-258,共2页Acta Chinese Medicine

摘　　要：目的观察培美曲塞联合洛铂或顺铂治疗晚期肺腺癌的疗效及不良反应.方法：将68 例晚期肺腺癌患者随机分成两组,其中39 例接受洛铂联合培美曲塞方案化疗（洛铂组）,即培美曲塞500 mg/m^2 静点d1,洛铂30mg/m^2 静点d1,3 周为1 周期;29 例接受顺铂联合培美曲塞方案化疗（顺铂组）,即培美曲塞500mg/m^2 静点d1,顺铂25mg/ m^2 静点d1-3.两组患者均接受至少2 个周期的化疗,比较两组疗效及毒副反应发生情况.结果：洛铂组总有效率56.4%（22/39）,顺铂组总有效率58.6%（17/29）,两组比较无统计学意义（P〉0.05）;洛铂组Ⅲ～Ⅵ度血小板下降发生率（6 例,15.4%）高于顺铂组（3 例,10.3%）,但差异无统计学意义（P〉0.05）;肾毒性、神经毒性发生率比较差异无统计学差异（P〉0.05）;洛铂组未出现Ⅲ～Ⅵ度胃肠道反应（0 例,0%）明显低于顺铂组（5 例,17.2%）,差异有统计学意义（P﹤0.05）.结论：培美曲塞联合洛铂或顺铂都是治疗晚期肺腺癌的有效方案,两者疗效相似,但洛铂胃肠道反应发生率低于顺铂,安全耐受性好.ObjectiveTo investigate the efficacy and toxicity of pemetrexeddisodium combined with lobaplatin or cisplatin for patients with advanced adenocarcinoma oflung.Method：68 patients with histologically diagnosed lung adenocarcinoma were divided in two groups. The LP regimen group （lobaplatin 30mg/m^2 iv d1, pemetrexeddisodium500mg/m^2 iv d1, 21days were a cycle） had 39 patients and the CP regimen group （cisplatin 25mg/m^2 iv d1-3, pemetrexeddisodium 500mg/m^2 iv d1, 21days were a cycle） had 29 patients.The efficacy and toxicity were evaluated after at least two cycles of chemotherapy. Results：The response rate （RR） in LP regimen group was56.4% （22/39）, while in CP regimen groupwas58.6%（17/29）. Grade 3-4 thrombocytopenia rate in LP regimen group （15.4%, 6/39） was higher in CP regimen group （10.3%, 3/29）, but there was no statistical difference betweenthe two groups （P〉0.05）.There was no difference between the two groups in nephrotoxicity and neurotoxicity.In LP regimen group, the incidence of grade 3-4 gastrointestinal reactionwas 0.0%（0/39）, and was17.2%（5/29） in CP regimen group on the contrary. The was significant difference between the two groups （P〈0.05）. Conclusion：Both LP and CP are safeand effective chemotherapy for patients with advanced lung adenocarcinoma.The effectiveness of lobaplatin with pemetrexeddisodium is similar to of cisplatin withpemetrexeddisodium in initial treatment of advanced adenocarcinoma of lung, but lobaplatin caused less gastrointestinal reaction. Lobaplatin is well tolerant and has less toxicity.

关 键 词：培美曲塞 洛铂 顺铂 肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]